EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy

Immune-Zytokin-Signatur sagt das Überleben bei Patient:innen mit fortgeschrittenem Melanom voraus, die mit dem onkolytischen Adenovirus TILT-123, Chemotherapie und IL-2-freier adoptiver TIL-Therapie behandelt werden

Lyna Haybout, Tatiana V Kudling, James H Clubb, Tine Juul Monberg, Benedetta Albieri, Santeri Artturi Pakola, Elise Jirovec, Victor Arias, Dafne C A Quixabeira, Susanna Juteau, Eva Ellebæk, Marco Donia und 16 weitere

Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e016003

DOI: 10.1136/jitc-2026-016003 ↗

Auf einen Blick

In der Phase-I-Studie TUNINTIL wurde TILT-123 mit TIL-Therapie ohne lymphodepletierende Chemotherapie oder IL-2 gegeben. Eine bestimmte Immun- und Zytokin-Signatur war mit günstigen bzw. ungünstigen klinischen Verläufen verbunden.

Fragestellung

Welche immunologischen und zytokinbezogenen Marker sind in der TUNINTIL-Studie mit dem klinischen Verlauf unter TILT-123 plus TIL-Therapie assoziiert?

Methode

Korrerelative Analyse einer offenen, multizentrischen, multinationalen First-in-human-Phase-I-Dosis-Eskalationsstudie; 17 Patient:innen; Immunprofiling im Blut und im Tumor, PCR, Neutralisationsantikörper; Follow-up bis März 2026.

Ergebnisse

Bei 17 Patient:innen zeigte sich früh eine angeborene Immunaktivierung mit NK-Zell-Expansion und Hochregulation zytotoxischer Gene, gefolgt von mehr intratumoralen T-Zellen. CD27+CD28+ memory-precursor CD8+ T-Zellen waren mit günstigen Verläufen, myeloide suppressive Zellen und angiogene/inflammatorische Zytokine mit Progression assoziiert.

Schlussfolgerung der Autor:innen

Die Befunde liefern mechanistische Einblicke in TILT-123 plus TIL-Therapie und sprechen für zukünftige biomarker-gestützte klinische Studien.

Kernaussagen

  • Frühe NK-Zell-Expansion und zytotoxische Genaktivierung wurden beobachtet
  • CD27+CD28+ memory-precursor CD8+ T-Zellen waren mit günstigem Verlauf assoziiert
  • Myeloide suppressive Zellen und angiogene/inflammatorische Zytokine mit Progression assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.08.2026. Verfasst von Lyna Haybout und 27 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Melanoma, Adenoviridae, Lymphocytes, Tumor-Infiltrating, Oncolytic Virotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: TILT Biotherapeutics Oy, Jane ja Aatos Erkon Säätiö, Syöpäsäätiö.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic melanoma resistant to immune checkpoint inhibitors remains difficult to treat, and while adoptive tumor-infiltrating lymphocyte (TIL) therapy has shown durable responses, its reliance on lymphodepleting chemotherapy and high-dose interleukin (IL)-2 causes toxicity that may limit patient eligibility. The dual-cytokine-armed oncolytic adenovirus igrelimogene litadenorepvec (TILT-123) was administered with TILs in the TUNINTIL trial (trial registration: NCT04217473 ) in patients with metastatic melanoma resistant to immune checkpoint inhibitors, without lymphodepleting chemotherapy or IL-2 post-conditioning. This study presents a correlative immunological analysis of the phase I TUNINTIL trial evaluating TILT-123 in combination with TIL therapy.

Methods

The TUNINTIL trial was a first-in-human, open-label, dose-escalation, multicenter, multinational phase I trial. 17 patients with checkpoint-inhibitor-resistant metastatic melanoma received up to six intratumoral TILT-123 injections followed by TIL infusion, without lymphodepleting chemotherapy or IL-2 post-conditioning. Systemic immune profiling (serum proteomics, flow cytometry, interferon-γ ELISpot assay), intratumoral immune cell–cell profiling (multiplex immunofluorescence, H&E, adenovirus E1a immunohistochemistry), quantitative PCR, and neutralizing antibody responses were assessed at defined time points through the trial, with survival follow-up updated to March 2026. Response criteria were evaluated using Response Evaluation Criteria in Solid Tumors V.1.1 and positron emission tomography-based criteria. Statistical analyses included Kaplan-Meier survival with log-rank tests, Mann-Whitney U tests, Pearson correlation, and receiver operating characteristic/area under the curve analysis for biomarker cut-off determination.

Results

Tumor biopsy analyses revealed an early innate immune activation marked by natural killer-cell expansion and cytotoxic gene upregulation, followed by increased intratumoral T-cell infiltration. This occurred without lymphodepleting chemotherapy or post-conditioning IL-2. Intratumoral viral DNA was detectable in a subset of patients. The enrichment of CD27+CD28+ memory-precursor CD8+ T cell was associated with favorable clinical outcomes. Elevated monocytic myeloid-derived suppressor cells and angiogenic/inflammatory cytokines following combination treatment were associated with disease progression, highlighting the role of immunosuppressive myeloid subsets as potential mediators of therapeutic resistance. Additionally, correlative analysis in pooled TILT-123 cohorts identified serum epidermal growth factor as a candidate biomarker for stratifying and monitoring patients.

Conclusions

These findings provide mechanistic insights into TILT-123 combined with TIL therapy and propose future directions for biomarker-guided clinical studies. Trial registration number NCT04217473 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAdenoviridaeLymphocytes, Tumor-InfiltratingOncolytic VirotherapyCytokinesImmunotherapy, AdoptiveOncolytic VirusesHumansFemaleMaleMiddle AgedAgedAdultCombined Modality TherapyInterleukin-2

Stichwörter der Autor:innen

Adoptive cell therapy - ACTBiomarkerCytokineOncolytic virusTumor infiltrating lymphocyte - TIL

Substanzen

CytokinesInterleukin-2

Autor:innen und Institutionen

  • Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • TILT Biotherapeutics Oy, Helsinki, Uusimaa, Finland.
  • Department of Oncology, Herlev Hospital National Center for Cancer Immune Therapy, Herlev, Denmark.
  • Herlev Hospital National Center for Cancer Immune Therapy, Herlev, Capital Region of Denmark, Denmark.
  • Department of Pathology, HUS Helsinki University Hospital, Helsinki, Finland.
  • National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital, Herlev, Denmark.

Förderung

  • TILT Biotherapeutics Oy
  • Jane ja Aatos Erkon Säätiö
  • Syöpäsäätiö
  • Sigrid Juséliuksen Säätiö
  • HUCH Research Funds
  • EU Horizon
  • Albert Ehrnrooth
  • Helsinki University Library

Zitieren

APA

Haybout, L., Kudling, T. V., Clubb, J. H., Monberg, T. J., Albieri, B., Pakola, S. A., Jirovec, E., Arias, V., Quixabeira, D. C. A., Juteau, S., Ellebæk, E., Donia, M., Løvendahl Eefsen, R., Borch, T. H., Lorentzen, T., Hendel, H., Vestergaard, C. D., Khammari, A., Kistler, C., …, & Hemminki, A. (2026). Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy. Journal for ImmunoTherapy of Cancer, 14(8), e016003. https://doi.org/10.1136/jitc-2026-016003

Vancouver

Haybout L, Kudling TV, Clubb JH, Monberg TJ, Albieri B, Pakola SA, et al. Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy. Journal for ImmunoTherapy of Cancer. 2026;14(8):e016003. doi:10.1136/jitc-2026-016003

BibTeX
@article{Haybout2026,
  author = {Haybout, Lyna and Kudling, Tatiana V and Clubb, James H and Monberg, Tine Juul and Albieri, Benedetta and Pakola, Santeri Artturi and Jirovec, Elise and Arias, Victor and Quixabeira, Dafne C A and Juteau, Susanna and Ellebæk, Eva and Donia, Marco and Løvendahl Eefsen, Rikke and Borch, Troels Holz and Lorentzen, Torben and Hendel, Helle and Vestergaard, Cecilie Dam and Khammari, Amir and Kistler, Claudia and Westergaard, Marie Christine Wulff and Met, Özcan and Sorsa, Suvi and Hemminki, Otto and Kanerva, Anna and Cervera-Carrascon, Victor and Dréno, Brigitte and Svane, Inge Marie and Hemminki, Akseli},
  title = {Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {e016003},
  doi = {10.1136/jitc-2026-016003}
}
Kostenlos starten →